GSK

News

Data backs GSK's ovarian cancer blockbuster hopes

GSK's B7-H4-targeting ADC Mo-Rez chalks up impressive results in ovarian and endometrial cancer, prompting a major phase 3 trials programme.

News

Meningitis outbreak in UK prompts call to widen vaccination

A UK patient group is calling for changes to the decade-old meningitis vaccination programme, after an outbreak in Kent killed two young people.

News

GSK's RSV shot cleared in US for all adults

GSK is back on level pegging with its rivals in the RSV vaccine category in the US, after getting FDA approval for Arexvy in the 18 to 49 age bracket.

News

Multicoloured letters with AUTISM spelled in the middle

FDA approves leucovorin – but not for autism

The FDA stops short of approving leucovorin for autism, but will its clearance for ultra-rare condition CFD-FOLR1 lead to more off-label prescribing?

News

Alfasigma licenses liver drug from GSK in $690m deal

With an FDA verdict looming, GSK has signed an eleventh-hour deal to give Alfasigma rights to its primary biliary cholangitis therapy linerixibat.

News

GSK grows pipeline with 35Pharma takeover, Frontier deal

GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

Data backs GSK's ovarian cancer blockbuster hopes

Meningitis outbreak in UK prompts call to widen vaccination

GSK's RSV shot cleared in US for all adults

FDA approves leucovorin – but not for autism

Alfasigma licenses liver drug from GSK in $690m deal

GSK grows pipeline with 35Pharma takeover, Frontier deal

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks